Appendix

Key Questions Reviewed by the Work Group and Member(s) Responsible for Literature Summary

Performance Characteristics

• Does the sensitivity and specificity of available tests for C. trachomatis and N. gonorrhoeae vary with respect to anatomic site from which the specimen was collected and/or specimen type?
  • Joan Chow, DrPH, California Department of Public Health, Richmond, California
  • Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland
• What recommendations should be made for the detection of C. trachomatis and N. gonorrhoeae infections of the genital tract, rectum, and throat?
  • Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut
  • Steven Shapiro, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
  • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
• What test recommendations should be made for the diagnosis of suspected LGV infections (inguinal and rectal presentations)?
  • Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Screening Applications

• What specimen types are optimal for of C. trachomatis and N. gonorrhoeae screening purposes?
  • Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland
  • Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California
  • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana
• What parameters should be considered when selecting a C. trachomatis and N. gonorrhoeae test for screening purposes?
  • George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois
  • Robert E Johnson, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
  • Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York

Economic Considerations

• What economic considerations might influence laboratory testing?
  • Thomas Gift, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Laboratory Confirmation

• What approaches, if any, can be used to derive a definitive laboratory confirmation of C. trachomatis and N. gonorrhoeae?
  • Yetunde Fakile, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
  • Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California
  • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
  • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana

Work Group Members
As of January 2009

Chair: John R. Papp, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia.

Presenters: Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut; Joan Chow, DrPH, California Department of Public Health, Richmond, California; George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois; Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California; Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland; Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California; Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota; Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana; Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland; Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York; Yetunde Fakile, PhD, Thomas Gift, PhD, Robert E Johnson, MD, Steven Shapiro, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia;

Consultants: Stefanie Akselrod, MS, Food and Drug Administration, Rockville, Maryland; James Beebe, PhD, San Luis Obispo County Health Agency, San Luis Obispo, California; Julius Schachter, PhD, University of California, San Francisco, California; Shari Shea, MPH, Association of Public Health Laboratories, Silver Spring, Maryland; Melissa Singer, MPH, Centers for Medicare and Medicaid Services, Baltimore, Maryland; Dean Willis, DrPH, Florida Department of Health (Retired), Jacksonville, Florida; Kimberly Workowski, MD, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC and Emory University, Atlanta, Georgia; Kelly Wroblewski, MPH, Association of Public Health Laboratories, Silver Spring, Maryland.